Each #BlueCrew member contributes to the Blueprint of our success, which hinges on responsibly delivering medicines to patients. With a steadfast focus on putting Patients First, Sam Tamulevich continuously monitors safety insights across our treatments to ensure the highest standards of excellence. Through collaboration with teams in Clinical Research, Regulatory, Biostatistics and beyond, he sees his belief that “it takes a village” come to life every day. Learn more:
Blueprint Medicines
Biotechnology Research
Cambridge, Massachusetts 61,858 followers
Striving to improve and extend patients' lives
About us
Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a proven track record of success with two approved medicines in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including systemic mastocytosis and chronic urticaria, breast cancer and other solid tumors. Patients are at the center of our mission. We know that in order to make a difference in their lives, we must create an environment where our employees — also known as the Blue Crew — can do their best work. Our culture of transparency, curiosity and diversity empowers us to draw upon a wide range of backgrounds and perspectives to build a conscientious team dynamic. Ideas come from every member of the Blue Crew, from the executive team to new hires. Each day, our teams commit to approach one another with respect and trust: a simple promise that fosters an inclusive and collaborative spirit. We care deeply about the communities where we live and work, and we strive to make a profound impact where it matters most. Learn more about who we are and explore our career opportunities at https://www.blueprintmedicines.com/careers/. Read our community guidelines: https://www.blueprintmedicines.com/community-guidelines/.
- Website
-
http://www.blueprintmedicines.com
External link for Blueprint Medicines
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2011
- Specialties
- targeted therapy, systemic mastocytosis, allergy/inflammatory, hematology/oncology, solid tumors, drug design, and mast cell biology
Locations
-
Primary
Get directions
45 Sidney St
Cambridge, Massachusetts 02139, US
-
Get directions
Baarerstrasse 8
Zug, 6300, CH
Employees at Blueprint Medicines
Updates
-
This week, we concluded another inspiring International Connection Summit (ICS), where our International Team came together to reflect on our achievements and advance our strategy for the year ahead. Throughout the week, our #BlueCrew connected with colleagues from across Europe, heard from physician and patient representatives, took part in volunteer activities and more. Thanks to all who joined us and helped deepen our impact for patients around the world.
-
We’re celebrating two years since the U.S. FDA approval of our treatment for indolent systemic mastocytosis (ISM). Over the past 15 years, we have honed our understanding of mast cell biology to tackle treatment challenges in this disease. As we build on our scientific, clinical and commercial expertise, we remain committed to driving continued innovation across systemic mastocytosis and the universe of allergic and inflammatory disorders. Read more in our latest blog: https://lnkd.in/eTDeCJNe
-
We recognize that early exposure to the life sciences industry opens new avenues for the talent of tomorrow. Recently, we partnered with Big Brothers Big Sisters of Eastern Massachusetts to welcome students from Edward M. Kennedy Academy for Health Careers and Quincy High School to our Cambridge office. During the visits, students toured our lab spaces, tested their knowledge in a game of Jeopardy and more. Below, Constance Carmona, M.Ed from Big Brother Big Sisters shares how career exposure field trips help students connect what they’re learning in school to real-world opportunities.
-
We’re proud to support RARE Revolution Magazine's mission to amplify the voices of rare disease communities. Through our collaboration, we're shining a light on systemic mastocytosis through the creation of a comprehensive resource to support patients throughout their journey. Read the magazine here: https://bit.ly/4duH9Ys
Vice President, Global Patient Affairs | CHIEF | CSC-MA Advisor | My Passion Archetypes: Healer-Altruist-Builder
I am proud to share the latest edition of Rare Revolution Magazine, SM edition, supported by Blueprint Medicines, and shaped by the voices of those living with systemic mastocytosis. This edition brings forward trusted information, personal insights, and a sense of connection for a community that too often faces delays in recognition and diagnosis. It shines a light on both the challenges and the resilience that define the rare disease experience. At Blueprint, our commitment extends beyond developing life-changing medicines. We believe advancing care means also supporting education, awareness, and community—because science alone isn’t enough to solve what people living with systemic mastocytosis face. We’re grateful to the individuals and advocates who shared their experiences so openly—and to Rare Revolution for building a platform where those stories can lead the way. I hope you’ll take a moment to read, reflect, and share. Because when rare voices lead, we all learn. https://lnkd.in/e6EeARTa #SystemicMastocytosis #PatientVoice #RareRevolution #BlueprintMedicines
-
When we take care of our mental health, we're better equipped to make a meaningful difference for ourselves, each other and the patients we serve. We're recognizing #MentalHealthAwarenessMonth with our annual Health & Well-Being Pop-Up in our Cambridge office, featuring a range of activities designed to support physical and mental wellness. From vision tests and biometric screenings to chair massages and nutrition tips, we’re committed to prioritizing our #BlueCrew's well-being this May and investing in wellness resources year-round. Read more from our Senior Director, Benefits Marie Noel below:
-
We were thrilled to welcome more than 100 #BlueCrew kids to our Cambridge office for our annual #BringYourKidstoWorkDay event. This year, the children dove into science experiments and learned what it takes to make medicines. We’re inspired by their enthusiasm each year, and we're proud to support STEM education and spark the imaginations of tomorrow’s scientists.
-
We’re proud to share our 2024 Sustainability Highlights, showcasing the recent progress of our sustainability strategy across environmental, social and governance principles. Our success is grounded in our demonstrated commitment to patients and our employees as we uphold good corporate citizenship and build a sustainable business for the long term. Read our latest report here: https://bit.ly/4jXs5EC
-
-
Earlier this year, we announced top-line results from the Phase 1 healthy volunteer trial of our wild-type KIT inhibitor. Just a few months later, we've initiated two out of four clinical proof-of-concept studies planned for this year, including in chronic urticaria. As we advance research in allergic and inflammatory diseases, we're moving rapidly into areas where targeting the mast cell through KIT inhibition plays a known role.
-
Today, we announced our Q1 2025 financial results. Join our live investor webcast at 8 a.m. ET or read our press release here: https://bit.ly/3RLlBfY
Similar pages
Browse jobs
Stock
BPMC
NASDAQ
20 minutes delay
$101.50
1.16 (1.156%)
- Open
- 99.14
- Low
- 98.25
- High
- 101.695
Data from Refinitiv
See more info on